7:50 am Chair’s Opening Remarks

Assessing Current Modelling Limitations & Emerging Trends to Drive Clinical Success

8:00 am Combination of a Multimeric Anti-DR5 IgM Antibody with Targeted Agents Induces Synergistic Tumor Cytotoxicity in Vitro & in Vivo


  •  Death receptor 5 (DR5) is activated upon receptor trimerization and induces cell death. IGM-8444 is a multivalent IgM antibody that efficiently clusters DR5 to induce potency tumor cytotoxicity
  • IGM-8444 has a good preclinical safety profile, enabling opportunities for rational combinations with targeted agents
  • Synergistic combinations were identified in vitr

8:30 am Leveraging PDX-derived Organoid (PDXO) Models for Combination Targeted Oncology


  • PDX-derived organoids are biologically equivalent to their matched PDX counterparts based on several shared characteristics
  • Screening of PDXO in a combination matrix approach enables rapid and valuable insight into combination strategies
  • A PDXO in vitro platform improves translatability of drug candidates, saves development time, and reduces animal usage by guiding optimal in vivo model selection for follow-on validation studies

9:00 am Translatability at a Glance: Combined Gene Edited & Engineered Cellular Therapies for Solid Tumors

  • Khalid Shah Vice Chairman at BWH, Harvard Medical School


  • Creating and characterizing cellular therapies for targeting multiple cell surface receptors on tumor cells and TME
  • Testing the efficacy of targeted cellular therapies in translatable tumor models
  • Defining a roadmap towards clinical translation

9:30 am Leveraging the Power of Novel Humanized Models to Support Preclinical Oncology Studies in the Context of Changing FDA Pre-IND Requirements

  • Andrew Puca Director, Corporate & Commercial Development, The Jackson Laboratory


  • Utilizing translational pre-clinical models for progressing drug discovery
  • Understanding clinical relevance of safety-tox in pre-clinical systems
  • How Jax is pushing the boundaries of innovation in humanized mouse platforms in drug-discovery

10:00 am Patient-Derived Cell (PDC) Models as a Tool to Assess Cancer Therapeutic Efficacy Across the Drug Development Life Cycle


  • PDC model development and characterization
  • Clinical response predictivity
  • HTS/HCI applications to assess cancer therapeutic efficacy, mechanism of action and patient stratification

10:30 am Morning Break & Structured Networking

Drug Discovery

Optimizing Technologies to Support Pre- Clinical Models

Track Chair: Jessica Haverkamp, Associate Director Macrophage Biology, BlueRock Therapeutics

11:15 am Fireside chat: Utilizing RNA-Seq for Better Pre-Clinical Predictions & Patient Identification


  • Screening for actionable targets based on targeted RNA-sequencing to make a more accurate prediction of drug efficacy
  • How to preserve the complexity of tumor biology in models?
  • Can we use RNAseq to understand MoA?
  • Can we use baseline RNAseq readouts as patients selection? Is this practical with a gene signature, or do we need to limit this to 1-2 genes to make this practical in clinical trials?

11:45 am Humanized Mouse Model as a Translational Tool for Immunotherapy in Oncology

  • Frank Sun Senior Principal Scientist, Oncology Pharmacology, Sanofi


  • Engineering human target in huPBMC GvHD model to construct a clinic translational model
  • Deepen understanding of tumor biology and therapeutic response of multiple specific Nanobodies
  • Donor selection and HLA match for improving treatment response

12:15 pm De-Risking Drug Development by Incorporating Clinically Correlated Ex Vivo Models


  • Clinically correlated ex vivo models are available to provide solutions to historical problems such as efficacy
  • Kiyatec’s models can be incorporated into every stage of drug development across multiple drug classes
  • Preclinical development can lead to clinical utilization

12:30 pm Treatment Modalities to Improve Response in Tumors Refractory to Standard Immunotherapy Approaches

  • Natalia Blanco Associate Director, Immuno-Oncology, Morphic Therapeutic


  • Low dose radiation in combination with immunotherapy in advanced tumors
  • Mechanistic insights into radioimmunotherapy resistance
  • Reversing immune dysfunction via interference of TGFbeta pathway with inhibitors of the integrin avB8

1:00 pm Q&A

Drug Development

Exploring Approaches to Dosing & Combination Administration Methods

Track chair: Katie Grausam Postdoctoral Scientist, Cedars Sinae

11:15 am Targeting c-MET in Combination with Radiation is Effective in MET-Fusion Driven High- Grade Glioma

  • Marc Zuckermann Group Leader Preclinical Modeling, German Cancer Research Center (DKFZ)


  • Inhibitor and radiation regimen selection for combinatorial in vivo trials
  • Validating preclinical results in multiple mouse models
  • Complementing in vivo data with PK and in vitro analyses

11:45 am Combination Therapy to Outsmart RASAddicted Cancer – Informing Clinical Strategy with Preclinical Modeling

  • Jingjing Jiang Senior Director, Translational Research, Revolution Medicines


  • Identify biomarkers that can help direct the “right combination regimen” to the “right patients”
  • Define upfront combination regimens that can prevent/ delay emergent resistance mechanisms to RevMed RAS(ON) inhibitors
  • Understand if/how we can translate learnings between distinct RAS mutations and cancer histotypes

12:15 pm Exploring Tumor Localized CD137 Agonism with Bicycle Tumor-Targeted Immune Cell Agonists (Bicycle TICAs®)


  • Description of the development of tumor-targeted immune cell agonists (Bicycle TICA™) based on constrained bicyclic peptides (Bicycles®) to activate costimulatory receptors selectively in the presence of tumor cells
  • Outlining the preclinical mechanistic data underlying the profound reprogramming of the tumor immune microenvironment
  • Highlighting translational aspects of work to inform clinical trials

12:45 pm Roundtable Discussion: Right Tumor, Right Model, Wrong Drug

  • Douglas Palmer Executive Director of Immuno-Oncology Translational Medicine, AstraZeneca


  • Getting the system right to evaluate drug utility

1:15 pm Networking Lunch

2:15 pm Precise and translational preclinical models for assessment of immune-targeting agents

  • Kader Thiam SVP Discovery - Preclinical Models & Services, Genoway


  • Outlining BRGSF-HIS mice: immunodeficient mice displaying functional human lymphoid and myeloid compartments, without side effects
  • Assessing efficacy and toxicity induced by immune checkpoint inhibitors, cell engagers and combo therapies in BRGSF-HIS mice, which displays a wide therapeutic window
  • Showcase of assessment of immune targeting agents in immune checkpoint humanized models

Tackling Metastasis: Modelling, Prevention & Treatment

2:45 pm Modeling Bone Metastasis of Prostate Cancer

  • Juan Arriaga Assistant Professor – Department of Oncological Sciences & Urology, Icahn School of Medicine at Mount Sinai


  • Develop mouse models to understand the way tumors metastasize and respond to therapy
  • What determines metastatic competency? Can we predict this by studying primary tumors?
  • What is the role of biomarkers to predict disease progression?

3:15 pm Session Reserved for Labcorp

  • David Draper Associate Director, Scientific Development, Labcorp


  • Cloudman S91 and YUMM1.7 melanoma models were evaluated following treatment with anti-mPD-1 and radiation therapy (RT) using flow cytometry and the NanoString® nCounter PanCancer IO 360™ panel
  • Cloudman S91 tumor growth was sensitive to checkpoint inhibition but not RT, while TUMM1.7 tumors responded only to RT
  • Treatment-induced immunophenotypic profiles and signaling pathway signatures were distinct between the two models and reflected the
    corresponding tumor growth kinetics, thus providing two unique preclinical tools for drug discovery

3:30 pm Afternoon Break & Poster Session


Come and join us for the poster presentation session, and vote for your favorite

3:50 pm Accelerating Antibody Research Using Humanized Mouse Models


  • Humanized components of the immune/oncology checkpoint pathways
  • Models for bi-specific antibody development
  • Next generation immunodeficient mice (NCG) for xenografts and better stem cell engraftment

4:20 pm Developing Clinically Translatable Models that Accurately Represent Patient Metastasis

  • Anita Seshire Head Of Laboratory in Exploratory Cancer Research, Translational Innovation Platform Oncology- Immunooncology, EMD Serono


  • Understanding physiological routes of metastasis
  • Identifying factors that influence dissemination
  • Understanding how the microenvironment contributes to metastasis

4:50 pm Preclinical Evaluation of Novel Combination Therapies Using Multigenic Humanized Models

  • Jenna Frame PhD, Sr. Manager, Scientific Communications & Marketing, Biocytogen


  • Introduce the use and advantages of humanized syngeneic mouse tumor models for evaluating preclinical efficacy, toxicity, and other mechanisms of action of antibody/biologic combination therapies
  • Outline the use of cell lines expressing tumor-associated antigens to evaluate dual checkpoint and TAA blockade in immune-checkpoint humanized mice
  • Describe the applicability of human immune system humanized mice, which includes highly immunodeficient (B-NDG) mice and second-generation B-NDG models with humanized cytokines to support human immune cell subpopulations, for evaluating immunotherapies against human tumor cells

5:20 pm Chair’s Closing Remarks & End of Conference Day One